Schrödinger, Inc. (SDGR)
NASDAQ: SDGR · IEX Real-Time Price · USD
22.76
-0.14 (-0.61%)
At close: May 17, 2024, 4:00 PM
22.52
-0.24 (-1.05%)
After-hours: May 17, 2024, 7:43 PM EDT
Company Description
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications.
The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations.
The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide.
Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrödinger, Inc.
| Country | United States |
| Founded | 1990 |
| IPO Date | Feb 6, 2020 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 867 |
| CEO | Dr. Ramy Farid Ph.D. |
Contact Details
Address: 1540 Broadway, 24th Floor New York, New York 10036 United States | |
| Phone | 503-299-1150 |
| Website | schrodinger.com |
Stock Details
| Ticker Symbol | SDGR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001490978 |
| CUSIP Number | 80810D103 |
| ISIN Number | US80810D1037 |
| Employer ID | 95-4284541 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ramy Farid Ph.D. | Chief Executive Officer, President and Director |
| Dr. Richard A. Friesner Ph.D. | Co-Founder, Scientific Advisory Chairman and Director |
| Dr. Geoffrey Craig Porges MBBS | Executive Vice President and Chief Financial Officer |
| Yvonne Tran Esq. | Chief Legal and People Officer |
| Dr. Robert Lorne Abel Ph.D. | Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling Research & Development |
| Dr. Karen Akinsanya Ph.D. | President of Research and Development Therapeutics |
| Jenny Herman | Senior Vice President of Finance and Corporate Controller |
| Prof. William Goddard III | Co-Founder and Scientific Advisor |
| Kenneth Patrick Lorton | Executive Vice President, Chief Technology Officer and Chief Operating Officer of Software |
| Shane Brauner | Executive Vice President and Chief Information Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2024 | 10-Q | Quarterly Report |
| May 1, 2024 | 8-K | Current Report |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 4, 2024 | 144 | Filing |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 28, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 28, 2024 | 10-K | Annual Report |